What are cytokines and why are Bio-Techne's R&D Systems cytokines the research standard?

Cytokines are signaling proteins produced by immune cells that coordinate immune responses — including interleukins (IL-1, IL-6, TNF-alpha, etc.), interferons, and growth factors. Researchers use recombinant cytokines (manufactured protein versions) to stimulate cells in culture, study signaling pathways, and validate assays. R&D Systems (Bio-Techne's legacy brand) became the standard reference cytokine source because: it established its catalog of cytokines early when alternatives were scarce; research publications cite specific R&D Systems catalog numbers, creating a chain of reproducibility that incentivizes future researchers to use the same product; and R&D Systems' consistent quality and characterization ensures experimental reproducibility. When a cytokine is cited in hundreds of peer-reviewed papers as 'R&D Systems cat# XXXX,' any researcher trying to reproduce those results buys from R&D Systems to ensure comparability.

How do cell and gene therapy manufacturing tools differ from research reagents?

Research reagents are sold in small quantities for lab experiments — a researcher might buy a 10µg vial of a cytokine for $300-500 for use in dozens of experiments. Cell and gene therapy manufacturing uses these same cytokines but at production scale — manufacturing a single CAR-T cell therapy dose for a patient requires growing tens of millions of T cells over 2 weeks, requiring large quantities of IL-2, IL-7, and other cytokines to maintain cell growth and function. A single batch of commercial CAR-T therapy might require milligrams of high-purity, GMP-grade cytokines costing $10,000-100,000. Bio-Techne provides both research grade and GMP (Good Manufacturing Practice) cytokines — the GMP versions command significant price premiums and create a new, higher-value customer segment as cell therapies move from clinical trials to commercial production.

What is the Simple Western technology and why did Bio-Techne acquire it?

Simple Western (Bio-Techne's ProteinSimple brand) is an automated system for Western blotting — a laboratory technique that identifies and quantifies specific proteins in a mixture by size and antibody binding. Traditional Western blotting is labor-intensive, requiring 8-24 hours of manual steps (gel electrophoresis, protein transfer, antibody incubation, imaging). Simple Western automates this into a 3-hour capillary electrophoresis workflow using microfluidics — researchers just load samples and get results. Bio-Techne acquired ProteinSimple because: it provides an instrument platform that generates recurring antibody consumable revenue; many researchers using Simple Western buy Bio-Techne antibodies for their experiments, creating a vertically integrated consumable opportunity; and automated Western blotting is an ideal application for researchers who want faster, more reproducible protein analysis in drug development workflows.

brimindinvest.com / compare / pki-vs-bio-techneLIVE

PKI

Revvity, Inc. (formerly PerkinElmer) · Healthcare - Life Science Tools & Diagnostics

N/A

N/A this month

VERSUS

⟷

COMPARE

TECH

Bio-Techne Corporation · Healthcare - Life Science Reagents

$57.94

+27.42% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

PKI

0

TECH

0

MIXED SETUP

Comparison scoreboard

MIXED SETUP

AI Score

PKI N/A

TECH 37.3

1Y Return

PKI N/A

TECH +17.05%

Fwd P/E

PKI N/A

TECH 28.19

Target Up.

PKI N/A

TECH +5.81%

Op. Margin

PKI N/A

TECH 25.19%

Metrics last refreshed: 6/22/2026

Quick take

PKI vs TECH Stock Comparison: AI Score, Valuation, Performance and Upside

PKI/Revvity and TECH (Bio-Techne) are both life science tools companies but with different product profiles — Revvity focuses on diagnostics instruments (newborn screening, immunodiagnostics) and research tools after divesting industrial businesses, while Bio-Techne is a reagents specialist with premium cytokines, proteins, and antibodies for research and the emerging cell and gene therapy manufacturing market. Revvity has more diagnostics exposure; Bio-Techne has more research consumables depth.

PKI vs TECH is life sciences diagnostics and instruments transformation story (Revvity's evolution from industrial instrumentation to pure life science diagnostics and tools after strategic divestitures) versus premium life science research reagents specialist (Bio-Techne's gold-standard cytokine and antibody franchise with cell and gene therapy manufacturing tools as the next growth vector) — diagnostics instruments versus research consumables.

Live analysis · updated 6/22/2026

PKI and TECH are closely matched — they split the tracked metrics evenly.

Normalized 1Y performance

PKI

TECH

Not enough data to chart yet.

Recent returns

PKI

TECH

Analyst price targets & sentiment

PKI

Price target data unavailable

N/A

TECH · 13 analysts

STRONG BUYHOLDSTRONG SELL

Buy (1.8/5.0)

Price target range

analyst low$51.00
analyst high$90.00
analyst mean$61.31
current price$57.94

+5.8% upside to analyst mean

Who should consider this stock?

PKI may suit investors who:

→Want a diagnostics-weighted life science tools company with stable newborn screening revenue providing revenue resilience across research spending cycles
→Value Revvity's transformation narrative — the PerkinElmer-to-Revvity strategic pivot to pure life sciences may unlock a higher valuation multiple as the industrial discount is removed
→Prefer a more balanced diagnostics/tools mix compared to Bio-Techne's research reagent concentration

TECH may suit investors who:

→Want the premium research reagents franchise — Bio-Techne's R&D Systems brand is deeply embedded in biomedical research literature and lab workflows, creating high-switching-cost recurring consumable revenue
→Value Bio-Techne's cell and gene therapy manufacturing tool positioning as a long-term growth vector as CGT therapies advance from clinical trials to commercial manufacturing at scale
→Prefer Bio-Techne's high-margin reagents business model with premium research brand differentiation versus more instrument-centric diagnostics companies

Performance & AI score

Metric	PKI	TECH
AI score	N/A	37.3
AI rank	N/A	#1413
Latest close	N/A	$57.94
1M return	N/A	+27.42%
6M return	N/A	+1.67%
1Y return	N/A	+17.05%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	PKI	TECH
1Y ago	N/A	$11.56K (+15.6%) started 2025-06-18
5Y ago	N/A	$5.44K (-45.6%) started 2021-06-21
10Y ago	N/A	$23.35K (+133.5%) started 2016-06-20

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	PKI	TECH
Market cap	N/A	$9.07B
Trailing P/E	N/A	82.77
Forward P/E	N/A	28.19
Price/Sales	N/A	6.31
EV/Revenue	N/A	7.55
Analyst target	N/A	$61.31
Target upside	N/A	+5.81%

Growth, profitability & risk

Metric	PKI	TECH
Revenue growth	N/A	-1.50%
Earnings growth	N/A	128.60%
EPS growth	N/A	+128.60%
FCF margin	N/A	+24.76%
Operating margin	N/A	25.19%
Profit margin	N/A	9.05%
ROIC proxy	N/A	5.34%
Return on equity	N/A	5.34%
Dividend yield	N/A	0.55%
Beta	N/A	1.36
Debt/equity	N/A	13.92
Current ratio	N/A	4.49
Quick ratio	N/A	2.80

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

PKI max drawdownN/A

TECH max drawdown39.34%

PKI max wkly dropN/A

TECH max wkly drop16.34%

5Y risk snapshot

PKI max drawdownN/A

TECH max drawdown67.35%

PKI max wkly dropN/A

TECH max wkly drop19.73%

10Y risk snapshot

PKI max drawdownN/A

TECH max drawdown67.35%

PKI max wkly dropN/A

TECH max wkly drop19.73%

Performance metrics by period

Period	Metric	PKI	TECH
1Y	Growth	N/A	+15.58%
	CAGR	N/A	+15.60%
	Sharpe ratio	N/A	0.45
	Max drawdown	N/A	39.34%
	Max daily drop	N/A	16.36%
	Max wkly drop	N/A	16.34%
5Y	Growth	N/A	-46.48%
	CAGR	N/A	-11.77%
	Sharpe ratio	N/A	-0.25
	Max drawdown	N/A	67.35%
	Max daily drop	N/A	16.36%
	Max wkly drop	N/A	19.73%
10Y	Growth	N/A	+120.70%
	CAGR	N/A	+8.24%
	Sharpe ratio	N/A	0.27
	Max drawdown	N/A	67.35%
	Max daily drop	N/A	16.36%
	Max wkly drop	N/A	19.73%

Business comparison

Category	PKI	TECH
Company	Revvity, Inc. (formerly PerkinElmer)	Bio-Techne Corporation
Sector	Healthcare - Life Science Tools & Diagnostics	Healthcare
Industry	N/A	Biotechnology
Core business	Revvity (formerly PerkinElmer, rebranded in 2023 after selling its industrial and environmental instrumentation businesses) is a life science tools and diagnostics company — providing newborn screening instruments and reagents, immunodiagnostics platforms, reproductive health testing, genomics and genomic analysis tools, and laboratory informatics software. Revvity's diagnostics business tests newborns for metabolic diseases and genetic disorders in hospitals globally.	Bio-Techne is a life science tools company providing high-quality proteins, cytokines, antibodies, assay kits, and cell and gene therapy manufacturing reagents used by researchers and drug developers globally. Bio-Techne's products (under brands R&D Systems, Tocris, Novus Biologicals, Simple Western) are critical components in basic biomedical research, drug discovery, and increasingly in cell and gene therapy manufacturing workflows.
Investor focus	Investors track Revvity's Life Sciences and Diagnostics segment revenue, reagent consumables growth (recurring revenue from installed instrument base), the transformation from PerkinElmer's industrial roots to a pure life sciences company after asset sales, and the biotech funding cycle's impact on research tool demand.	Investors track Bio-Techne's protein/cytokine segment organic growth, reagents business trends, cell and gene therapy (CGT) tool revenue as a growing segment, operating margins (historically very high reflecting the premium nature of its research reagents), and the competitive moat of its R&D Systems brand in research cytokines.

PKI strengths

→Newborn screening market leadership — Revvity's instruments and reagent kits are used in newborn screening programs globally; testing newborns for 50+ metabolic and genetic disorders is a government-mandated public health function providing stable recurring revenue
→Immunodiagnostics installed base with recurring reagents — Revvity's immunoassay platforms generate recurring consumable reagent revenue as installed hospital laboratory analyzers require proprietary reagents for ongoing testing
→Life sciences transformation under new identity — the Revvity rebranding after selling industrial businesses signals strategic focus on life science tools and diagnostics markets with better growth profiles than industrial instrumentation

TECH strengths

→Premium cytokine and protein research reagents franchise — Bio-Techne's R&D Systems brand is the gold standard reference source for cytokines, growth factors, and proteins used in biomedical research; researchers cite R&D Systems products specifically in publications, creating brand loyalty and switching costs
→High-margin consumables business — research reagents have very high gross margins (70%+); once a researcher validates a specific antibody or protein in their assay, they reorder the same catalog number repeatedly rather than validating alternatives
→Cell and gene therapy manufacturing reagents growth — Bio-Techne's cytokines and proteins are used to culture CAR-T cells and other cell therapies; as cell and gene therapy advances from research to commercial manufacturing, Bio-Techne's role in the manufacturing supply chain grows

Risks to watch — PKI

→Post-COVID diagnostics normalization — Revvity's diagnostics business benefited from COVID testing demand; normalization has reduced near-term diagnostics revenue versus peak COVID years
→Competitive intensity in immunodiagnostics — large IVD companies (Roche, Abbott, Siemens Healthineers) dominate hospital lab analyzers; Revvity's differentiation in specific niches (newborn screening, reproductive health) requires maintaining technological leadership
→Life science tool spending sensitivity to biotech funding — Revvity's research tools business is influenced by pharmaceutical and biotech R&D spending levels

Risks to watch — TECH

→Academic and biotech research budget sensitivity — Bio-Techne's research reagent demand is tied to NIH grant funding (academic research) and biotech venture funding; budget pressures at either source reduce reagent purchases
→Competition from Thermo Fisher, Merck KGaA (Sigma-Aldrich), and Chinese reagent suppliers offering lower-cost alternatives to Bio-Techne's premium cytokines and antibodies
→Cell and gene therapy market development pace — CGT manufacturing tool demand is a major growth thesis for Bio-Techne; if cell and gene therapy commercialization is slower than expected, this growth vector underwhelms

Frequently asked questions

Newborn screening is a public health program that tests newborns (typically via a heel-prick blood spot collected within 24-48 hours of birth) for dozens of serious but treatable metabolic, genetic, and endocrine disorders. Conditions screened include phenylketonuria (PKU), congenital hypothyroidism, cystic fibrosis, sickle cell disease, and many others. Early detection enables treatment before serious neurological damage or other complications occur — a critically important public health intervention. In the U.S., all 50 states mandate newborn screening panels; similar mandates exist in most developed countries. This mandatory public health function creates stable, recurring demand for Revvity's newborn screening instruments and proprietary reagent panels regardless of research funding cycles or pharmaceutical industry conditions.

AI Prediction SignalNext 5 trading days

Members only

PKI

+2.8%BUY

TECH

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides